ILOPERIDONE: NEWER ATYPICAL ANTIPSYCHOTIC FOR SCHIZOPHRENIA

  • Shakti B Dutta Department of Pharmacology, SGRRIM&HS, Patel Nagar, Dehradun, India
  • Mirza Atif Beg
  • Amanjot Kaur Department of Pharmacology, SGRRIM&HS, Patel Nagar, Dehradun, India
  • Subhash Vishal Department of Pharmacology, SGRRIM&HS, Patel Nagar, Dehradun, India

Abstract

The optimal treatment of schizophrenia poses a challenge to develop more effective treatments and safer drugs, to overcome poor compliance, discontinuation and frequent switching with available antipsychotics. Many antipsychotic medications are currently approved by FDA for the treatment of schizophrenia, but response to these agents remains highly variable. Iloperidone is a new dopamine type 2/serotonin type 2A (D2/5-HT2A) antagonist structurally related to risperidone, expected to give better efficacy with less extrapyramidal symptoms than D2 receptor antagonist antipsychotics. Iloperidone is more efficacious in terms of cognitive functions, less problematic regarding weight gain and metabolic disturbances.

Keywords: iloperidone, pharmacology, pharmacokinetics, efficacy, safety

 

Downloads

Download data is not yet available.

Author Biographies

Shakti B Dutta, Department of Pharmacology, SGRRIM&HS, Patel Nagar, Dehradun, India

Department of Pharmacology, SGRRIM&HS, Patel Nagar, Dehradun, India

Amanjot Kaur, Department of Pharmacology, SGRRIM&HS, Patel Nagar, Dehradun, India
Department of Pharmacology, SGRRIM&HS, Patel Nagar, Dehradun, India
Subhash Vishal, Department of Pharmacology, SGRRIM&HS, Patel Nagar, Dehradun, India
Department of Pharmacology, SGRRIM&HS, Patel Nagar, Dehradun, India

References

1. Lavie A, Michael A, Megan J. A novel atypical antipsychotic for the treatment of schizophrenia. Formulary 2008; 43:190-203.
2. Tonin FS, Wiens A, Llimos FF, Pontarolo R. Iloperidone in the treatment of schizophrenia- an evidence based review of its place in therapy. Core Evid 2016; 11:49-61.
3. Cutler AJ, Kalali AH, Mattingly GW, Kunovac J, Meng X. Long term safety and tolerability of iloperidone: results from a 25week, open label extension trial. CNS Spectr. 2013;18(1):43–54.
4. Albers LJ, Musenga A, Raggi MA. Iloperidone: a new benzisoxazole atypical antipsychotic drug. Is it novel enough to impact the crowded atypical antipsychotic market? Expert Opin Investig Drugs 2008; 17:61-75.
5. Kongsamut S, Roehr JE, Cai J, et al. Iloperidone binding to human and rat dopamine and 5-HT receptors. Eur J Pharmacol 1996; 317:417–23.
6. Kalkman HO, Subramanian N, Hoyer D. Extended radioligand binding profile of iloperidone: A broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders. Neuropsycho pharmacology 2001; 25:904–14.
7. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors: Focus on newer generation compounds. Life Sci. 2000; 68:29-39.
8. Kalkman HO, Feuerbach D, Lotscher E, Schoeffter P. Functional characterization of the novel antipsychotic iloperidone at human D2, D3, alpha2C,5-HT6 , and 5-HT1A receptors. Life Sci. 2003; 73:1151–59.
9. CacciaS, Pasina L, Nobili A. New atypical antipsychotics for schizophrenia: Iloperidone. Drug Des Devel Ther. 2010:4:33-48.
10. Subramaian N, Kalkman HO. Receptor profile of P88-8991 and P95-12113, metabolites of the novel antipsychotic iloperidone. Prog Neuropsycho pharmacol Biol Psychiatry. 2002;26 :553-60.
11. Jain KK. An assessment of iloperidone for the treatment of schizophrenia. Expert Opin Investig Drugs. 2000; 9(12):2935–43.
12. Sainati SM, Hubbard JW, Chi E, Grasing K, Brecher MB. Safety, tolerability, and effect of food on the pharmacokinetics of iloperidone (HP 873), a potential atypical antipsychotic. J Clin Pharmacol. 1995; 35:713–20.
13. Potkin SG, Litman RE, Torres R et al. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. J Clin Psycho pharmacol. 2008; 28(suppl 1):S4-11.
14. Cutler AJ, Kalali AH, Weiden PJ et al. Four week, double-blind, placebo and ziprasidone controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psycho pharmacol 2008; 28(suppl1):S20-8.
15. Weiden PJ, Cutler AJ, Polymeropoulos MH et al. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivitol trials. J Clin Psycho pharmacol 2008; 28(suppl 1):S12- 9.
16. Kane JM, Lauriello J, Laska E et al. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia. J Clin Psychopharmacol 2008; 28(suppl 1):S29-35.
17. Dutta A, Baruna S, Dan A, Chakraborty K, Mandal M. Iloperidone-induced galactorrhea in middle aged female. Indian J Psychol Med.2012; 34(4):396-98.
18. Dargani NV, Malhotra AK. Safety profile of iloperidone in the treatment of schizophrenia. Expert Opin Drug Saf 2014; 13(2):241-46.
19. Citrome L, Weiden PJ, Alva G, Glick ID, Jackson R, Mattingly G, Kianifard F et al. Switching to iloperidone: An omnibus of clinically relevant observations from a 12week, open label, randomized clinical trial in 500 persons with schizophrenia. Clin Schizo phr Relat Psychoses 2015; 8(4):183-95.
20. Weiden PJ, Manning R, Wolfgang CD, Ryan JM, MancioneL, HanG, Ahmed S, Mayo MG. Randomized trial of iloperidone for prevention of relapse in Schizophrenia: The REPRIEVE study.CNS Drugs 2016;30(8):735-47.
Statistics
110 Views | 138 Downloads
How to Cite
1.
Dutta S, Beg M, Kaur A, Vishal S. ILOPERIDONE: NEWER ATYPICAL ANTIPSYCHOTIC FOR SCHIZOPHRENIA. JDDT [Internet]. 14May2017 [cited 4Apr.2020];7(3):8-0. Available from: http://jddtonline.info/index.php/jddt/article/view/1441